XML 24 R18.htm IDEA: XBRL DOCUMENT

Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Percentage of Product Sales and Accounts Receivable Balance

The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:


	Net Product Sales						Accounts Receivable
	Three Months Ended June 30, 2024			Six Months Ended June 30, 2024			As of June 30, 2024
Customer A(1)		46.0	%		45.1	%		45.7	%
Customer B		34.6	%		36.2	%		35.1	%
Customer C		18.3	%		17.7	%		18.8	%
Total		98.9	%		99.0	%		99.6	%

(1)

Includes net product sales and accounts receivable balances for a subsidiary of Customer A that were reported separately in the Company’s Form 10-Q for the three months ended March 31, 2024, filed with the SEC on May 7, 2024.

Schedule of Disaggregated Net Product Sales

The following table provides disaggregated net product sales (in thousands):


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2024		2023		2024		2023
CINVANTI net product sales	$	24,927	$	24,474	$	50,544	$	47,329
SUSTOL net product sales		4,246		2,836		7,860		5,819
ZYNRELEF net product sales		5,831		4,128		10,844		7,661
APONVIE net product sales		1,020		324		1,446		568
Total net product sales	$	36,024	$	31,762	$	70,694	$	61,377

Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):


	Product Returns			Distributor Fees			Discounts, Rebates and Administrative Fees			Total
Balance at December 31, 2023	$	4,776		$	4,419		$	27,334		$	36,529
Provision		(1,216	)		14,212			101,867			114,863
Payments/credits		(517	)		(12,969	)		(100,890	)		(114,376	)
Balance at June 30, 2024	$	3,043		$	5,662		$	28,311		$	37,016

Common Stock Equivalents Excluded From Computation of Net Loss Per Share

Because we have incurred a net loss for all periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss, the following common stock equivalents were not included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):


	June 30,
	2024		2023
Stock options outstanding		27,445		28,778
Restricted stock units outstanding		1,642		2,732
Warrants outstanding		298		8,548
Shares of common stock underlying convertible notes outstanding		9,819		9,819